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the MLP to the trial data showed that timolol-treated patients
had a higher risk of developing night IOP peaks than travoprost-
treated patients. The estimates were 57.8% versus 58.2% (P <
0.90) respectively for travoprost and latanoprost using 8:00
IOPs, but 43.6% versus 50.0% (P < 0.05) with 10:00 IOPs, and
43.9% versus 53.3% (P < 0.005) using 16:00 IOPs. CONCLU-
SION: IOP measures during the day are correlated with night
measures. The MLP results suggest that control of IOP in late
afternoon might also prevent night IOP peaks. Prostaglandin
analogues were associated with a lower probability of late after-
noon and night time IOP peaks than timolol. The travoprost
night IOP peak probability was lower than that for latanoprost.
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OBJECTIVE: To conﬁrm randomized clinical trial results
showing that travoprost reduces IOP with sustained efﬁcacy 
in the afternoon, 20–24 hours after the last instillation.
METHODS: Patients treated with a prostaglandin analogue
monotherapy for ocular hypertension or glaucoma was included
in this cross-sectional retrospective survey. Demographics, anam-
nesis, previous treatments were collected from medical chart.
IOP and the last instillation time were collected during the visit.
ANOVA, logistic regressions and propensity scores were used to
compare the 2 treatments. RESULTS: 2503 patients were
included by 494 ophthalmologists. Patients averaged 64 years
old (45% male). 2052 patients were treated with travoprost or
latanoprost and the last instillation time was documented for
1702 of them. 1241 patients had properly used their medication
within the previous day and 461 patients had failed to take it.
IOP was 25mmHg at diagnosis and 22.5mmHg at the initiation
of the current treatment. The two groups were comparable but
travoprost-treated patients had a shorter disease and treatment
duration. When the instillation was given during the day before,
travoprost better controlled IOP at 12.00 and 16.00 hours
(16.79 versus 17.51mmHg; P < 0.05) and after 16.00 (16.55
versus 17.67mmHg; P < 0.003). When the interval time between
the instillation and IOP recordings was >24 hours, travoprost-
treated patients had a lower IOP (16.76 versus 17.80mmHg; P
< 0.002). The percentage of patients reaching the pre-deﬁned
target IOP was higher with travoprost than with latanoprost,
independent of instillation time (81.9% versus 67.3% (P <
0.0001) when intake was the previous day, and 78.5% versus
68.3% (P < 0.03) when intake >24 hours. These differences per-
sisted after adjustment for confounding factors. CONCLUSION:
This observational survey conﬁrmed the previous clinical data
demonstrating that travoprost uniformly controls IOP through
the day with a strong remnant effect, since IOP remains well con-
trolled for more than 24 hours.
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OBJECTIVES: The purpose of this study was to assess the incre-
mental effect on intraocular pressure (IOP) reduction when
changing from latanoprost-timolol ﬁxed combination in the
treatment of primary open-angle glaucoma (POAG).
METHODS: Retrospective analysis was conducted of the
Glasgow Royal Inﬁrmary Glaucoma database. The database was
comprised of computerized medical records of all POAG patients
treated at the Glasgow Royal Inﬁrmary from 1981 to present.
Data elements recorded for each patient included demographics,
diagnosis, and treatment history. Treatment history included
initial and subsequent medication regimens. Patient IOP was
measured before and after treatment change and mean change
with 95% C.I. was calculated. RESULTS: Eighty-three cases of
POAG were identiﬁed where treatment was changed from
evening dosed latanoprost to latanoprost-timolol once daily to
achieve or maintain lower target IOP. The mean incremental
reduction in IOP was 2.01mmHg (95% C.I. 1.22–2.81). 
CONCLUSIONS: In POAG patients treated with latanoprost
who require lower target pressures to control their disease,
latanoprost-timolol ﬁxed combination provides additional incre-
mental IOP reduction. Additional research should be conducted
to further characterize and understand the importance of efﬁcacy
of combination therapy in the treatment of glaucoma.
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OBJECTIVE: To compare the efﬁcacy of latanoprost, bimato-
prost and travoprost for controlling IOP using data published 
in the literature. METHODS: Randomized clinical trials were
identiﬁed on Medline and Embase using the following key
words: glaucoma, ocular hypertension, randomization, trial,
latanoprost, bimatoprost and travoprost. The trials had to
compare at least two prostaglandins head-to-head in monother-
apy. Cross-over experimental designs were excluded. Sample
size, IOP at inclusion and ﬁnal visit, age, gender, race and period
of follow-up were collected. Daily average IOP was estimated
when measurements were available over the study period.
Latanoprost was used as the reference treatment for compar-
isons. Multiple regression analyses estimated the effects of the
different treatments on IOP after controlling for IOP at inclu-
sion and duration of follow-up. All analyses were weighted using
number of patients (inversely proportional to variance weights).
RESULTS: A total of 224 papers were identiﬁed, including 15
randomized clinical trials, which compared two prostaglandin
monotherapies. Six studies were excluded: three cross-over
designs, one with daily intake not in accordance with the SmPC,
one combination study, and one without documented average
IOP. The average age varied from 56.7 to 68.8 years and the IOP
at inclusion from 22.3 to 26.5mmHg. 378 patients were treated
with bimatoprost, 385 with travoprost and 548 with
latanoprost. After adjusting for baseline IOP and period of
follow-up, both patients treated with travoprost and bimato-
prost tended to have a lower IOP (-0.63mmHg [-1.56; 0.30]
and -0.78 mmHg [-1.75; 0.18], respectively) than those treated
with latanoprost. After adjusting for IOP at baseline, follow-up
period, age and gender the treatment effects were -0.72 [-2.02;
0.57] and -0.69 [-2.04; 0.65] for travoprost and bimatoprost,
respectively. CONCLUSION: Based on the information available
in the literature, travoprost and bimatoprost may have greater
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efﬁcacy than latanoprost in controlling the IOP for patients with
ocular hypertension or glaucoma.
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OBJECTIVE: This study aimed at estimating the potential public
health impact of Retaane 15mg (anecortave acetate suspen-
sion)in age-related macular degeneration. METHODS: Based on
clinical trial results and literature, a Markov model was built to
compare anecortave acetate to best supportive care (BSC) during
the lifetime of ARMD patients. Patients entering the model were
75 years of age with a new diagnosis of wet ARMD in one eye.
This model took into account the efﬁcacy of anecortave acetate
to slow deterioration and delay visual disability, the probability
for a patient to develop the disease in the fellow eye, and mor-
tality. Results of the model were expressed in terms of duration
of low vision (with blindness in one eye) and blindness in both
eyes. Health consequences of blindness and low vision were esti-
mated for depression and hip fractures as well as for institu-
tionalization. Duration of the model was 25 years and the cycle
length was 1 month. The fellow eye could be affected in 30% of
the patients at ﬁve years. Premature mortality associated with
blindness and low vision was estimated. RESULTS: Anecortave
acetate decreased the number of prevalent blind cases by 20%
and the average time with blindness by 30%. Depression preva-
lent cases were decreased by 21% and those with hip fracture
by 10%. The number of patients who were institutionalized was
decreased by 27%. Decrease in life expectancy due to premature
mortality associated with blindness and low vision could be esti-
mated at 17% in the BSC group and 15.5% in the anecortave
acetate group. Life expectancy was increased by 3 months.
CONCLUSION: Anecortave acetate presents important and
favorable potential public health outcomes in patients with wet
ARMD. According to the model it could reduce the rates of
depression, hip fractures and institutionalization, and increase
life expectancy compared with BSC.
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OBJECTIVE: To estimate the number of treatable eyes with wet
sub-foveal ARMD in France. METHODS: Surveys documenting
wet ARMD incidence rate were searched in the literature. Direct
standardization according to age and gender was performed
using INSEE demographic data. Projection at year 2025 was per-
formed using OECD data. A 75 years old cohort was simulated
using a 7-states Markov model. Mean treatment duration of
New Chemical Entity is not known today and therefore was
ﬁxed arbitrarily at 2 years. The probability to develop ARMD
in the fellow eye was ﬁxed at 30% at 5 years. Monthly death
incidence rate was modeled from INSEE mortality tables. The
time horizon of the model was 25 years and the cycle length 
one month. Sensitivity analyses were performed. RESULTS: 3
surveys were identiﬁed. The Rotterdam Study, the only one per-
formed in the EU, was chosen as the best proxy for France. In
2005, 30,192 citizens will develop ARMD in the ﬁrst eye; of
those 17,585 will be wet and 13,805 will be wet sub-foveal
(Olsen, 2004). Taking into account the fellow eye, mortality and
the base case scenario treatment duration, the number of wet
sub-foveal treatable eyes would be 37,019. Treatment duration
is the most sensitive parameter of the model. Number of eyes
would be 18,899, 53,204, 67,535, and 80,162 for a treatment
duration of 1, 3, 4 and 5 years, respectively. The number of treat-
able eyes will increase by 7.1% if probability to develop the
disease in the second eye is 40%, and decrease by -9.0% if it is
20%. A 2% yearly increase is expected till 2025 due to popula-
tion aging and the 1950s’ baby-boom. CONCLUSION: Accord-
ing to our model, the number of sub-foveal wet ARMD treatable
eyes would be 37,019, in France. Average treatment duration
was the most sensitive parameter.
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OBJECTIVE: LASEK is one of the current surgical technique to
correct refractive errors of the eye, such as myopia, hyperopia,
and astigmatism. In this method, the corneal epithelial ﬂap is
lifted then replaced after laser ablation of the subepithelial
cornea. The hinged ﬂap is created by epithelial marking and
exposure of the marking ethyl alcohol (20%) for 5 seconds.
METHODS: LASIK (Laser in Situ Keratomileusis) is a surgical
procedure to correct myopia by corneal stroma subtraction. It
involves the use of a microkeratome to make a lamellar dissec-
tion of the cornea creating a ﬂap with intact corneal epithelium.
After the ﬂap is lifted, the underlying midstroma is reshaped with
an excimer laser and the ﬂap is returned to its original position.
We have detected eighteen cases where the treatment of patients
that had been subjected to LASEK with polyvinyl alcohol artiﬁ-
cial tear drops provoked eye adverse effects. Toxicogenic kerati-
tis, partial epithelium detachment, and allergic and toxicogenic
conjunctivitis were observed. These adverse effects disappeared
upon discontinuing tear drops administration and reappeared
after their reintroduction. We used the Naranjo et al. algorithm
to conﬁrm the cause-effect relationship. RESULTS: All cases
were conﬁrmed as deﬁnitive. CONCLUSION: We have not
observed any case of eye adverse effect in patients subjected to
LASIK caused by polyvinyl alcohol tear drops.
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OBJECTIVE: To develop a health-economic assessment for
Macugen, a new treatment for age-related macular degeneration
(AMD). A comprehensive model compares Macugen (pegap-
tanib sodium), indicated for all patients with neovascular AMD,
relative to the existing photodynamic therapy with Visudyne
(verteporﬁn). METHODS: A Markov framework was used to
model the lifetime movement of an AMD cohort through ﬁve
